In summary, our study demonstrates that JMJD2D can antagonize the p53 tumor suppressor and activate an oncogenic signaling pathway (such as Wnt/β-catenin signaling pathway) simultaneously to drive liver tumorigenesis, suggesting that JMJD2D may serve as a novel target for liver cancer treatment. This evidence concerns the gene TP53 and liver cancer.